Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Shanghai Institute of Digestive Disease, Inflammatory Bowel Disease Research Center, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Respirology, Baoshan Branch, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Front Public Health. 2023 Jun 15;11:1115127. doi: 10.3389/fpubh.2023.1115127. eCollection 2023.
The SARS-CoV-2 Omicron variant caused a large-scale outbreak of COVID-19 in Shanghai, China. Patients with inflammatory bowel disease (IBD) are at high risk of infection due to immunosuppressive interventions. We aimed to investigate the vaccination information of patients with IBD and update a vaccination guide based on a comparison of vaccination in asymptomatic carriers and healthy individuals.
This retrospective study was conducted during an Omicron variant wave. We assessed the vaccination status in patients with IBD, asymptomatic carriers and healthy individuals. Factors with unvaccinated status and adverse events following vaccination were also determined in patients with IBD.
The vaccination rate was 51.2% in patients with IBD, 73.2% in asymptomatic carriers, and 96.1% in healthy individuals. Female sex ( 0.012), Crohn's disease ( 0.026), and disease behavior of B3 ( 0.029) were factors that indicated a lower vaccination rate. A significantly higher proportion of healthy individuals had received one booster dose (76.8%) than asymptomatic carriers (43.4%) and patients with IBD (26.2%). Patients with IBD received vaccination without an increased risk of adverse events ( 0.768).
The vaccination rate of patients with IBD remains much lower than that of asymptomatic carriers and healthy individuals. The COVID-19 vaccine has been found to be safe among all three groups and patients with IBD are not more susceptible to adverse events.
SARS-CoV-2 奥密克戎变异株在中国上海引发了 COVID-19 的大规模爆发。由于免疫抑制干预，炎症性肠病（IBD）患者感染风险较高。我们旨在调查 IBD 患者的疫苗接种信息，并基于无症状感染者和健康个体的疫苗接种比较，更新疫苗接种指南。
本回顾性研究在奥密克戎变异株流行期间进行。我们评估了 IBD 患者、无症状感染者和健康个体的疫苗接种状况。还确定了 IBD 患者未接种疫苗的因素和接种后不良事件。
IBD 患者的疫苗接种率为 51.2%，无症状感染者为 73.2%，健康个体为 96.1%。女性（ 0.012）、克罗恩病（ 0.026）和 B3 疾病行为（ 0.029）是疫苗接种率较低的因素。健康个体接受一剂加强针的比例明显高于无症状感染者（76.8%）和 IBD 患者（26.2%）。IBD 患者接种疫苗没有增加不良事件的风险（ 0.768）。
IBD 患者的疫苗接种率仍然远低于无症状感染者和健康个体。COVID-19 疫苗在这三组人群中均被证明是安全的，且 IBD 患者不易发生不良事件。
